Emergent BioSolutions (NYSE:EBS) inks a formal agreement
with the U.S. government aimed at speeding up the development of a
plasma-based therapy, COVID-HIG, a human hyperimmune (contains a lot of
antibodies against SARS-CoV-2) product for the potential treatment of
severely ill COVID-19 patients and high-risk acute symptomatic patients
to prevent progression to severe symptoms.
The company has initiated plasma screening and collection and intends to seek emergency use authorization from the FDA.
The U.S. Department of Health and Human Services’
Biomedical Advanced Research and Development Authority (BARDA) will
provide $14.5M in funding to support development.
NIH’s National Institute of Allergy and Infectious
Diseases (NIAID) has agreed to incorporate COVID-HIG into one of its
clinical trials.
https://seekingalpha.com/news/3558007-emergent-bio-teams-up-feds-to-expedite-plasma-therapy-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.